BRIEF REVIEW www.jasn.org

Frailty and Protein-Energy Wasting in Elderly Patients with End Stage Kidney Disease

Jun Chul Kim,*† Kamyar Kalantar-Zadeh,*‡§‖ and Joel D. Kopple*§‖

*Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California; †Division of Nephrology, CHA Gumi Medical Center, CHA University, Gumi-si, South Korea; ‡Harold Simmons Center for Kidney Disease Research and Epidemiology, Torrance, California; §David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; and ‖University of California, Los Angeles Fielding School of Public Health, Los Angeles, California

ABSTRACT

Older people constitute an increasingly greater proportion of patients with advanced CKD, including those patients undergoing maintenance dialysis treatment. Frailty is a biologic syndrome of decreased reserve and resistance to stressors that results from cumulative declines across multiple physiologic systems and causes vulnerability to adverse outcomes. Frailty is common in elderly CKD patients, and it may be associated with protein-energy wasting (PEW), sarcopenia, dynapenia, and other complications of CKD. Causes of frailty with or without PEW in the elderly with CKD can be classified into three categories: causes primarily caused by aging *per se*, advanced CKD *per se*, or a combination of both conditions. Frailty and PEW in elderly CKD patients are associated with impaired physical performance, disability, poorer quality of life, and reduced survival. Prevention and treatment of these conditions in the elderly CKD patients often require a multifaceted approach. Here, we examine the causes and consequences of these conditions and examine the interplay between frailty and PEW in elderly CKD patients.

J Am Soc Nephrol 24: 337–351, 2013. doi: 10.1681/ASN.2012010047

Older patients comprise an increasing proportion of people with stage 5 CKD and those patients undergoing maintenance hemodialysis (MHD) or chronic peritoneal dialysis (CPD).[1–4] Frailty and protein-energy wasting (PEW) are common complications in elderly patients with ESRD undergoing MHD or CPD.[2,5–9] This phenomenon is clinically relevant, because many manifestations of frailty and PEW are strong risk factors for low quality of life (QOL), morbidity, and mortality.[3,5,10,11] Frailty and PEW may be caused by aging, advanced kidney failure, or both conditions combined. Here, we review causes, consequences, and potential therapies for frailty and PEW in elderly ESRD patients.

DEFINITIONS

The US National Library of Medicine defines aged in humans as ages 65–79 years old. Individuals >79 years old are categorized as aged 80 years and over. Frailty can be defined as a biologic syndrome of decreased reserve and resistance to stressors that results from cumulative declines across multiple physiologic systems and causes vulnerability to adverse outcomes.[11] Frailty implies decreased body energy and protein reserves and reduced strength. There are several excellent discussions of frailty in CKD patients.[2,6,12,13] A simple criterion for frailty can be the presence of three or more of the following abnormalities: unintentional weight loss, self-reported exhaustion, measured weakness, slow walking speed, and low physical activity.[11–13]

PEW is defined as the loss of somatic and circulating body protein and energy reserves.[14] The term PEW is used rather than protein-energy malnutrition, because some causes of PEW are unrelated to inadequate nutrient intake.[9,14,15] Causes of PEW in ESRD patients include inadequate nutrient intake, losses of nutrients during dialysis, superimposed catabolic illnesses, nonspecific inflammation, acidemia, catabolic stress from the dialysis procedure, low levels of or resistance to such anabolic hormones as insulin, growth hormone, and IGF-1, increased levels of such catabolic hormones as parathyroid hormone and glucagon, blood losses from blood drawing or gastrointestinal bleeding,[9,15] and possibly, oxidative and carbonyl stress.[16–20]

Two related concepts are sarcopenia and dynapenia. Sarcopenia is derived from the Greek words sarx (flesh) and penia (loss).[21] Two common definitions for sarcopenia are progressive decline in

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Prof. Joel D. Kopple, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502. Email: jkopple@labiomed.org

muscle mass caused by aging, which results in decreased functional capacity of muscles,[22] or simply, decreased muscle mass in the elderly.[23] Dynapenia, derived from the Greek words dyn (power) and penia (loss), is defined as loss of strength with aging.[23,24] These definitions may not be optimal, because reduced muscle mass and strength are not always present in people≥65 years old, and morbidity, malnutrition, or just physical inactivity can reduce muscle mass and strength in younger people.[24] Skeletal muscle (SKM) mass size seems to be the most important predictor of muscle strength or physical performance[25] and in maintenance dialysis patients, survival.[26,27] However, SKM mass and strength can be disassociated.[28] As normal people age, the rate of decline in muscle strength is greater than the rate of loss of muscle mass,[29] and strength can diminish even while muscle mass is maintained or increases.[30]

Physical performance is defined as the capability to conduct normal daily physical activities. Physical performance is often measured by such activities as the time required to climb a defined number of stairs or the distance walked or number of rises from a chair during a given time period.[31] Physical performance and mortality may be associated more with muscle strength than muscle mass.[32–34] Another age-related change in body composition, sarcopenic obesity,[35] refers to low muscle mass (sarcopenia) combined with increased body fat (obesity).[36] Sarcopenic obesity may develop without weight changes if the decrease in muscle mass is similar to the gain in body fat.[37]

INCREASED PREVALENCE OF FRAILTY AND PEW IN ELDERLY ESRD PATIENTS

Frailty and PEW are well described in adult ESRD patients independent of age. PEW is found in 18%–75% of maintenance dialysis patients in different reports.[9,13,38] There is less information concerning the prevalence and magnitude of these abnormalities in elderly ESRD patients. However, PEW (low serum albumin and subjective global assessment), sarcopenia (reduced mid-arm muscle circumference [MAMC]), and dynapenia (decreased hand grip strength) seem to be more common in older (>65 years) than younger maintenance dialysis patients.[39] In MHD patients, decreased lean body mass[40] and thigh muscle area[41] are associated with aging. The prevalence of sarcopenia also increases with aging in CKD patients without ESRD.[8] However, muscle wasting tends to be more severe in maintenance dialysis patients than dialysis-independent CKD patients.[42] Sarcopenic obesity is more pronounced in aging nondiabetic MHD patients than aging controls.[43] The volume of visceral fat, standardized by body mass index, is greater in nondiabetic MHD patients (mean age=57.5±1.3 years) compared with people with normal kidney function of similar age.[44]

Compared with the prevalence of frailty in elderly community-dwelling people (6.9% in the Cardiovascular Health Study[11] and 16.3% in the Women's Health Initiative[45]), frailty is substantially greater in elderly and near-elderly ESRD patients (67.7% in 2275 maintenance dialysis patients ages 58.2±15.5 years in the Dialysis Morbidity and Mortality Wave 2 Study).[6] The prevalence of frailty increases with age in MHD patients.[6] Moreover, elderly nondialyzed patients with primarily stage 3 CKD (mean age=76 years) had a greater prevalence of frailty (15% versus 6%; $P<0.001$) than elderly persons (mean age=72 years) with normal or mildly reduced kidney function.[14]

CAUSES OF FRAILTY AND PEW IN ELDERLY ESRD PATIENTS

Current thinking and scientific evidence regarding the many causes of frailty and PEW are well reviewed, and they are illustrated in Figure 1 and listed in Table 1 according to whether, in the authors' opinion, the causes are kidney failure, aging, or both factors.[9,46] The relative contributions of aging and ESRD to frailty and PEW may also be heavily influenced by such individual characteristics as the person's genotype, phenotype, medical history, duration and severity of renal failure, psychosocial condition, and lifestyle.

The causes of the aging process and its potential contributions to frailty are the foci of much research. These causes can be categorized into genetic and environmental exposure, including epigenetic factors.[16,47,48] Hundreds of genetic variations have been identified that are associated with longevity in various species.[16,47] Interestingly, a number of these genetic variations involve the insulin pathways including insulin, IGF, their receptors, and the signal transduction system that they induce.[47,49,50] Alterations that suppress activity of this pathway seem to be particularly associated with increased longevity. The finding that, in many species, reducing intake of calories or other nutrients increases longevity might be related to the fact that carbohydrates and some amino acids stimulate release of insulin, IGF-1, or the major IGF binding protein in serum. The elderly may be growth hormone (GH)-deficient.[51] IGF-1 exerts anabolic, anticatabolic, and antiapoptotic actions on SKM, and it helps to maintain SKM mass and enhance physical performance.[52,53] There is an age-related decline in IGF-1 activity that stems from the decline of GH; this decline may result in loss of muscle mass and strength and reduced exercise capacity.[54] Whether this decline promotes longevity is unknown.

Other environmental disorders that might contribute to aging include mitochondrial dysfunction and oxidative stress.[55,56] The accumulation of free radicals[48,57] may play a particular role in inducing age-related sarcopenia[16] and DNA damage, protein crosslinking, nonenzymatic glycation or other carbonyl reactions with proteins, accumulation of partially or completely denatured proteins, and cellular inflammation, which is commonly present in the aged.[58,59] Cellular apoptosis[48] and autophagy,[60,61] leading to loss of functional parenchymal cells, may increase along with failure of normal replacement by stem cells.[62] In addition,



Figure 1. Potential causes of frailty and protein-energy wasting in elderly patients with end stage kidney disease. $1,25(OH)_2D_3$, 1,25-dihydroxycholecalciferol; ESKD, end stage kidney disease; PTH, parathyroid hormone; VDR, vitamin D receptor.

the limits of cellular replication cycles because of telomere shortening[48,63,64] as well as DNA damage and oncogene expression in aging lead to the accumulation of dysfunctional senescent cells, which may contribute to dysfunctional tissues and organ systems.[48,65] Immune function also declines with aging.[48,66] Chronic inflammation also plays an important role in the aging process.[48,66–68]

Hormonal dysfunction with low levels or resistance to many hormones, including sex hormones, testosterone, insulin, IGF-1, and thyroid hormone, may occur. Deficiency of 25-hydroxyvitamin D [25(OH)D] has become common in industrialized societies because of reduced time spent in sunlight and the frequent use of sunscreen or clothing that covers the skin.[69] Increasing age does not alter intestinal absorption of dietary vitamin D, but it is associated with lower 25(OH)D levels, regardless of season.[69] Decreased dietary vitamin D intake and reduced cutaneous synthesis of vitamin D, possibly related to decreased skin thickness, may contribute to lower serum 25(OH)D in the elderly.[70] The normal elderly with low (<25 nmol/L) serum 25(OH)D levels are at higher risk for sarcopenia (assessed by dual-energy X-ray photon absorptiometry [DEXA]; odds ratio=2.14) and dynapenia (assessed by grip strength; odds ratio=2.57) compared with elderly persons with high serum levels (>50 nmol/L).[71] Vitamin D supplementation in the elderly improves lower extremity muscle performance[72] and increases the number and diameter of type II muscle fibers.[73] ESRD patients are also likely to develop deficiency of both serum 1,25-dihydroxycholecalciferol, which is primarily synthesized in the kidney, and 25(OH)D. MHD patients receiving calcitriol (1,25-dihydroxyvitamin D) or paricalcitol (a 1,25-dihydroxyvitamin D analog) showed larger thigh muscle cross-sectional area measured by magnetic resonance imaging ($P<0.05$) and greater lower limb muscle strength ($P<0.05$) compared with MHD patients without either treatment.[74] Because vitamin D deficiency has a direct association with type II muscle fiber atrophy and physical performance,[75,76] vitamin D deficiency, particularly if advanced, may cause severe dynapenia, which may improve dramatically with supplements of 1,25-dihydroxyvitamin D.

Aging is associated with changes in central and peripheral nervous system activity, which affect SKM structure and function.[77–79] Loss of lower motor neurons in the lumbospinal segments (L1–L3) is observed in people>60 years old.[80] Doublet discharges from motor neuron axons are considered to increase both the rate and amount of force production in SKM and slow muscle fatigue development. The frequency of doublet discharges is lower in older individuals (74.1±8.8 years) than young subjects (21.9±3.6 years).[81] The number and diameter of motor axons,[80] peroneal nerve conduction velocity (a measure of nerve myelination), and compound muscle action potentials (a measure of axonal degeneration)[82] all decrease with age. Compound muscle action potential is positively correlated with calf muscle density (a measure of fatty degeneration in muscle) assessed by computerized tomography.[82]

Table 1. Clinical causes promoting frailty and PEW in elderly CKD patients

Clinical Causes
1. Reduced food intake
Anorexia caused by uremic toxins (RF), other anorexigens (TNF-α, cholecystokinin, or leptin; RF), impaired sense of taste/smell (RF,A), inflammation (RF,A), emotional depression (RF,A), or medications (RF,A)
Dementia (A)
Poverty (RF,A)
Loss of teeth or loss of dentures (A)
2. Dialysate and urine nutrient losses (RF)
Losses of protein into dialysate (~1 g/HD with MHD; ~9 g/d with CPD)
Losses of amino acids into dialysate (~10–12 g/HD with MHD; ~2.0–3.5 g/d with CPD)
Losses of protein into urine and nephrotic range proteinuria
3. Catabolic effects
Nonspecific inflammation (RF,A)
Oxidant stress (increased oxidants, including advanced glycation end products and advanced lipid end products, and decreased levels or activities of antioxidants: vitamins E, C, selenium, or glutathione; RF,A)
4. Inflammation associated with clinically apparent diseases
Medical illnesses (*e.g.*, diabetes, infection, heart failure, or cancer) and surgical illnesses (RF,A)
5. Increased levels or activities of catabolic hormones
Parathyroid hormone (RF), glucagon (RF), corticosteroids (RF), or angiotensin II (RF)
6. Deficiency or resistance to anabolic hormones
Insulin (RF,A), growth hormone (RF, A), IGF-1 (RF,A), testosterone (RF,A), 25(OH)D_3 (RF,A), or 1,25-dihydroxycholecalciferol (RF)
7. Metabolic acidemia (RF)
Activates the caspase-3 and the ubiquitin–proteasome system in skeletal muscle, promoting protein catabolism
Suppress protein synthesis
8. Primary neuromuscular disorders
Central nervous system dysfunction
Specific neuronal changes (RF,A)
Dementia (A)
Peripheral nervous system dysfunction (RF,A)
Muscular changes
Loss of myocytes (A)
Reduced numbers of satellite cells and myogenic factors (RF,A)
Tendon stiffness (RF,A)
9. Physical inactivity and deconditioning (RF,A)
10. Accelerated/impaired apoptosis (A)
11. Increased number of senescent cells (A)
12. Decreased cellular replenishment by stem cells (A)
13. Reduced autophagy (A)
14. Accumulation of chemically altered proteins (RF,A)
15. Impaired DNA repair (RF,A)
16. Epigenetic alterations (RF,A)
17. Genetic predisposition (A)

The disorder was estimated to be caused by RF (chronic kidney failure), A (aging), or RF,A (both chronic kidney failure and aging).

With aging, the loss of fast motor units (type II fibers) because of denervation is more pronounced than the loss of slow motor units (type I fibers).[46] Denervated muscle fibers are recruited by surviving motor units and change their fiber type to the type of the surviving motor unit. Hence, there is a net conversion of type II fibers to type I fibers.[46] Type II fiber-specific TNF-α signaling is another pathway that may account for the preferential loss and atrophy of type II muscle fibers with advancing age.[83] Predominant atrophy of type II fibers is also observed in MHD patients (ages 44.1±17.2 years).[84]

Satellite cells (muscle stem cells) from older mice show reduced number and impaired myoblast generation and differentiation.[85] In SKM of elderly men (76±1 years) compared with young men (20±1 years), the percent of type II fibers was lower (47±3% versus 57±3%; $P<0.05$), and the total cross-sectional area of the type II fibers was significantly reduced ($P<0.05$).[86] The number of satellite cell per millimeter squared of type II muscle fibers was reduced in the elderly men compared with young men (9.7±1.0 versus 12.6±0.9, respectively; $P<0.05$).[86] Aging is associated with decreased or delayed expression of myogenic regulatory factors, which regulate satellite cell proliferation and differentiation. These factors include myogenic determination factor, myogenic regulatory factor 5, and myogenin.[87] The number of fibers in the vastus lateralis muscle and the motor units in the extensor digitorum brevis muscles begin to decline at approximately 50 and 60 years of age, respectively, in the general population.[88,89] Possibly because of some of the foregoing neuromuscular disorders, muscle protein synthesis in the elderly in the general population (70±6 years) shows decreased sensitivity and responsiveness to essential amino acids compared with young men (28±6 years).[90] Formerly, when access to dialysis was often delayed or not possible, severe neuropathy was often observed in patients with advanced CKD and ESRD. This uremic neuropathy, which often presents clinically with impaired sensation, could progress to hypoesthesia, reduced deep tendon reflexes, paresis, and ultimately, frank paralysis.

Tendons from older people (ages 69–80 years) are ~15% more compliant than tendons from younger people (ages 20–26 years). This compliance may lead to force reduction and slower contractile force transmission from muscles to bones.[91] In ESRD patients, calcium deposits may accumulate in tendons.[92,93] Tendons in both elderly people and ESRD patients have an increased

likelihood of rupturing or separating from their bony insertion when subjected to increased contractile force.[93,94] ESRD patients may also fracture bones with intense muscle contraction.[95,96] Scarring and loss of parenchymal function may occur from physical trauma, acute illnesses, and high prevalence of chronic diseases and other disorders, including hypertension, obesity, diabetes mellitus, atherosclerosis, osteoarthritis, physical deconditioning, and depression. Skeletal muscle mass within the lower 10th percentile of normal is observed in up to 62% of dialysis patients.[97]

Physical activity, in general, is decreased in dialysis patients and tends to decrease with age in both the general population[98] and MHD patients.[99] Decline in physical activity with advancing age, measured by accelerometry, is much greater for MHD patients than sedentary people without kidney disease.[99] Dialysis patients are likely to describe a greater reduction in moderate or vigorous physical activity with aging.[100] Physical inactivity in dialysis patients (ages 60±14 years) is associated with lower serum albumin and serum creatinine levels, which are indicative of PEW and small SKM mass.[101] In contrast, increased levels of physical activity, measured by accelerometry, are associated with higher lean body mass, assessed by DEXA, in MHD patients (ages 47±2 years).[102] In MHD patients (ages 64±11 years), physical activity for ≥50 min/d is associated with faster normal ($P<0.001$) and maximum ($P<0.001$) walking speed, greater leg strength ($P=0.04$), and better functional reach ($P=0.02$) compared with MHD patients with physical activity <50 min/d.[103] In elderly dialysis patients, reduced frequency of daily physical activity is correlated with higher mortality risk ($P<0.05$).[104]

Reduced food intake in advanced CKD is often caused by anorexia, which may be caused by uremic toxins, inflammation, superimposed illnesses and depression, or other psychiatric disorders. In support of an anorexia-causing role for uremic toxicity in patients treated with conventional maintenance dialysis, quotidian MHD seems to be associated with increased energy and protein intake.[105,106] Dietary protein intake is lower in normal elderly men (68.5±4.7 years) than normal younger men (25.6±3.7 years).[107] The median age of incident ESRD patients was 64.2 years in 2008[4] in the United States; hence, aging *per se* may contribute to their reduced nutrient intake. Dementia is not uncommon in elderly ESRD patients and may reduce food intake. People with ESRD commonly are less affluent and may have inadequate funds to purchase food. Even an edentulous state may impair the ability of ESRD patients to eat. Vintage (duration) of MHD is negatively associated with intake of energy ($r=-0.89$, $P<0.01$) and protein ($r=-0.05$, $P<0.05$).[108] Losses of amino acids, peptides, and water-soluble vitamins into dialysate may contribute to PEW and frailty.

Kidney failure intensifies and adds to many of the processes associated with aging. Kidney failure *per se*, like aging, engenders inflammation. In advanced CKD, there is impaired removal of proinflammatory cytokines (*e.g.*, increased serum C-reactive protein, TNF-α, and IL-6) and exposure to inflammatory stimulants (*e.g.*, uremic toxins), including those toxins engendered by the dialysis procedure itself (dialysis catheters, tubing, dialyzer membranes, and impure dialysate).[9] Inflammation also may result from clinically apparent superimposed illnesses (Table 1). Inflammation not only stimulates protein degradation and SKM wasting[109] but also suppresses appetite,[110,111] stimulates resistance to insulin and GH,[112] and enhances energy expenditure.[113] Aging *per se* predisposes to chronic inflammation.[114] A higher inflammatory state is associated with parenchymal fibrosis, less muscle mass and strength, and lower physical performance and functionality in the elderly.[114]

In chronic kidney failure as well as aging, there is also increased oxidant stress with enhanced generation of reactive oxygen species (ROSs), elevated serum oxidants, and reduced levels of antioxidants (Table 1).[115,116] ROS-induced mitochondrial injury, where the ROSs are primarily generated, has been invoked as a key cause of the aging process, although this theory has recently been challenged.[117,118] Both inflammatory cytokines and ROSs stimulate the ubiquitin–proteasome system. Oxidative stress caused by aging may cause atrophy and loss of muscle fibers[17]; oxidative stress may not be associated with muscle fiber atrophy in MHD patients.[18] There are increased levels of protein carbonyls, such as[58,119] advanced glycation endproducts[120,121] and advanced lipid endproducts,[121] which cause damage by reaction with endogenous proteins. Protein carbonyls, an indicator of oxidative damage to proteins, are directly associated with grip strength ($\beta=-6.77$, $P<0.01$) and decline in walking speed ($P=0.002$) in normal women≥65 years old.[19,20]

Genetic and epigenetic factors influence the propensity of individuals to develop CKD and the manifestations of the ESRD syndrome.[122–124] As with aging, kidney failure engenders a cascade of changes in gene function, cell signaling, and metabolism that, ultimately, leads to expression of many of the phenotypic characteristics of the aged person.[60,61,117,118,125]

Serum levels of gluconeogenic hormones (glucagon and parathyroid hormone) are increased, and there is resistance to anabolic hormones (insulin, growth hormone, and IGF-1) in ESRD.[126] Vitamin D deficiency, obesity, metabolic acidemia, inflammation, and accumulation of uremic toxins contribute to insulin resistance in advanced CKD.[127] Insulin resistance in ESRD may activate caspase-3 and the ubiquitin–proteasome system, thereby enhancing muscle protein degradation.[128,129] Insulin also stimulates protein synthesis. In nondiabetic MHD patients, insulin resistance is closely associated with SKM protein breakdown ($R^2=0.49$, $P=0.006$).[128] In diabetic compared with nondiabetic MHD and CPD patients, insulin resistance may contribute to greater loss of SKM during the first year of dialysis treatment[130,131]; diabetes mellitus was the strongest predictor of lean body mass loss in this study.[130] Older adults, ages 70–79 years, with type 2 diabetes and without ESRD also show

greater declines in leg muscle mass compared with nondiabetes.[132] SKM from chronic renal failure rats shows reduced IGF-1 mRNA levels and IGF-1 protein, resistance to the IGF-1–induced suppression of protein degradation and stimulation of protein synthesis, increased IGF-1 receptor mRNA and IGF-1 receptor number, and impaired receptor tyrosine kinase activity. These findings suggest abnormal IGF-1 physiology and reduced sensitivity to IGF-1 in chronic renal failure.[133] This pattern of skeletal muscle mRNA for IGF-1 and IGF-1 receptor is also observed in MHD patients.[134,135]

Male MHD patients not uncommonly have low serum testosterone.[136] A progressive decline in serum testosterone occurs with aging in normal men.[137] Low serum free testosterone is associated with frailty in elderly men.[138] Treatment with supraphysiological doses of testosterone may increase muscle size and strength in otherwise normal men.[139]

Metabolic acidemia, which is common in CKD because of impaired ability of the kidney to excrete acid, promotes frailty and PEW in many ways. Acidemia enhances intracellular protein degradation by activating caspase-3 and the ubiquitin–proteasome system,[129,140,141] reduces protein synthesis,[142] causes growth hormone and insulin insensitivity, and engenders negative protein balance.[143] Metabolic acidemia causes bone loss, more rapid progression of kidney failure in CKD patients, other endocrine disorders, systemic inflammation with increased proinflammatory cytokines, enhanced β2-microglobulin formation, and hypertriglyceridemia.[143–145] Severe metabolic acidemia (*e.g.*, arterial blood pH$\leq$7.25) may be associated with anorexia, reduced food intake, malaise, and hypotension.

CLINICAL CONSEQUENCES OF FRAILTY AND PEW IN ELDERLY ESRD PATIENTS

Frailty and PEW are associated with impaired physical performance, poorer quality of life, and reduced survival in elderly ESRD patients (Figure 2).[7,27,146] In MHD patients ages 63$\pm$14 years, age-related decreases in SKM mass and increases in fat mass (intramuscular and intermuscular adipocytes) are associated with decreased isometric strength and impaired physical performance (6-minute walk test and gait speed).[147] Reduced anterior tibialis muscle mass, which is more common in MHD patients than age- and sex-matched sedentary controls without advanced CKD, is significantly associated with reduced gait speed and isometric ankle dorsiflexor strength.[148] MHD patients (ages 53$\pm$15 years) with lower MAMC had worse mental health scores, which was assessed by the Short Form 36-item health survey (SF-36) questionnaire, and poorer survival.[26]

ESRD in adults of any age is associated with decreased physical performance. Scores of the Short Physical Performance Battery, an indicator of physical performance, are significantly lower in MHD patients compared with normal values for the elderly population in the Established Populations for Epidemiology Research in the Elderly, although the age of the MHD patients averaged 20 years younger than the elderly normals.[149] The physical functioning subscale of the SF-36 questionnaire in these MHD patients was also reduced.[149] In MHD patients$>$60 years (median age=75 years), both sit-to-stand scores and staircase climbing scores showed 50% and 54% fewer cycles, respectively, compared with age- and sex-matched control subjects without CKD.[150]

The foregoing findings mirror the effects of aging in the general population. In the elderly, the rate of decline in cognitive activity is positively correlated with increasing frailty[151] and decreasing muscle strength.[79] Moreover, the National Health and Nutrition Examination Survey Study indicates that normal adults$\geq$55 years old (mean=70.1 years) with obesity and dynapenia have poorer physical function (walking speed) than adults without these two disorders.[152] Increased fat mass rather than decreased fat-free mass is associated ($P<0.01$) with reduced physical capacity (walking speed) in normal people ages 68–82 years.[153]

Frailty and dynapenia are also associated with adverse clinical consequences. In adult maintenance dialysis patients in the Dialysis Morbidity and Mortality Wave 2 Study, frailty compared with no frailty is associated with greater hospitalization risk (adjusted hazard ratio [HR]=1.56, 95% confidence interval [CI]=1.36–1.79) and higher mortality (adjusted HR=2.24, 95% CI=1.60–3.15).[6] In the general population, decreased whole-leg extension strength exposes the elderly to more falls.[154] MHD patients$\geq$65 years old commonly fall; in one study, 27% of patients fell in the previous 12 months, and another 16% of patients fell before the past year.[155] Fall rates in elderly MHD patients ($\geq$65 years) were higher than rates in community-dwelling elderly people without CKD (1.6 versus 0.6–0.8 falls/person-year).[156] Impaired physical performance (10-m walking test) increases the risk of falls and fall-related fractures in elderly MHD patients.[157] Falls are independently associated with increased mortality (adjusted HR=1.78, 95% CI=1.07–2.98, P=0.03) in elderly MHD patients.[158]

Impaired neuromuscular function, which was indicated by increased get-up-and-go time, reduced functional reach, and slower 6-minute walk test, is associated with an increased risk of bone fracture in MHD patients,[146] roughly one-half of whom were elderly (mean age=66$\pm$9 years). The Dialysis Outcomes and Practice Patterns Study of MHD patients (mean age$\sim$60 years), sampled from 12 countries, indicated that their yearly incidence of hip fracture was much higher than the general population (age$\sim$60–65 years; 0.89% versus 0.07%–0.22%).[95,96] Among maintenance dialysis patients from the Dialysis Morbidity and Mortality Study (age=61.7$\pm$15.5 years), those patients who sustained a hip, vertebral, or pelvic fracture had a 2.7 times greater mortality than those patients who did not sustain such fractures.[159]

In direct contrast to the general population, body mass index is inversely related to mortality in MHD and CPD patients.[160–162] One hypothesis advanced to explain this observation is that obese MHD patients and CPD patients often have greater muscle mass than nonobese



Figure 2. Clinical consequences of frailty and protein-energy wasting in elderly patients with end stage kidney disease.

patients.[163–166] Larger SKM mass, indicated by higher serum creatinine or MAMC, increased body fat mass, and gain in SKM mass or body fat are each independently associated with increased survival in nonelderly and elderly MHD and CPD patients,[27,167,168] although it is still unclear why SKM mass or obesity should promote longer lifespan. Muscle mass may be more important than fat mass for survival.[27] Obesity combined with sarcopenia may be considered a form of PEW, and it is associated with inflammation and increased mortality in MHD and CPD patients.[169] In MHD patients, the location of the increased fat mass influences mortality. In MHD patients with a mean age of 65 years (range=51–74 years), such as in the general population, excess abdominal fat seems to be associated with higher mortality rate.[170]

MANAGEMENT STRATEGIES FOR FRAILTY AND PEW IN ELDERLY ESRD PATIENTS

Because frailty and PEW usually have multiple causes in elderly dialysis patients, prevention and treatment generally require a multifaceted approach. This subject is the focus of many studies and reviews.[9,13,46,129] This section and Table 2 briefly summarize potential strategies for prevention and treatment.

Good Medical/Nephrology Care

We are unaware of any randomized prospective interventional trials that have assessed the effects of preventing or improving frailty or PEW on clinical outcomes of elderly ESRD patients. However, observational data indicate that, in general, the better the clinical status of the patient commencing dialysis, the better the prognosis for survival.[171,172] PEW at the onset of dialysis is associated with poorer survival.[171,172] Starting dialysis before patients develop PEW is associated with better long-term nutritional status and lower mortality.[15,171,172] Indeed, commencement of dialysis is often associated with improvement in protein-energy status.[173,174] Better control of uremia may lead to less frailty and PEW. Experience with quotidian hemodialysis suggests that more than two times per week MHD treatments and larger doses of dialysis may improve patients' appetite, food intake, nutritional status, and QOL and reduce frailty and PEW.[106,175]

Intuitively, it would seem that advanced CKD and ESRD patients who have inflammatory catabolic illnesses and are treated promptly and aggressively with attention to their nutritional needs should have better clinical outcomes with less frailty and PEW. Moreover, given the high prevalence of oxidative, carbonyl, and inflammatory stress in ESRD patients, there should be a role for agents that correct these disorders. Anti-inflammatory and antioxidant drugs have been used in many trials of dialysis patients, most without apparent success.[176–178] However, rather small-scale studies indicate that the antioxidants α-tocopherol and *N*-acetylcysteine may reduce adverse cardiovascular events in MHD patients.[179,180] Hopefully, with further development, anti-inflammatory, antioxidant, or anticarbonyl drugs will be shown to reduce frailty and PEW and improve morbidity and mortality.

Nutrient Intake

Clearly, prevention and treatment of frailty and PEW require adequate intake

Table 2. Potential preventive and therapeutic strategies for frailty and PEW in elderly ESRD patients

Strategies
1. Start maintenance dialysis in a timely manner
2. Treat comorbid conditions aggressively; timely institution of increased protein/amino acid intake, enteral tube feedings, and iv nutrition
3. Consider optimal frequency/duration/dose of dialysis
4. Anti-inflammatory agents, antioxidants, anticarbonyl compounds? (several clinical trials are in progress)
5. Prescription of optimal dietary energy and protein intakes
6. Dietary counseling and monitoring as needed
7. Use of food supplements, enteral tube feeding, intradialytic nutrition, nutritional peritoneal dialysis, and nutritional hemodialysis
8. Prevent and treat acidemia; optimal arterial blood pH=7.40–7.45?
9. Use of anabolic hormones and other compounds
Insulin
Growth hormone
IGF-1
Carnitine
Anabolic steroids testosterone, nandrolone decanoate, decadurabolin, etc.
10. Exercise training

Many of these interventions have not yet been proven to be effective and safe in large-scale clinical trials.

of nutrients. Space does not allow for a detailed discussion of nutritional requirements in clinically stable and stressed ESRD patients, and reference is made to published reviews.[38,181,182] Multivitamin and trace element supplements are commonly needed.[181,183] Most expert groups recommend similar amounts of dietary protein intake (DPI) for adult MHD and CPD patients, ranging from 1.0 to 1.3 g/kg per day with at least 50% of the DPI of high biologic value.[182] It has been suggested that a safe protein intake that maximizes the probability of good protein nutrition for clinically stable MHD and CPD patients is 1.2 g/kg per day and 1.2–1.3 g/kg per day, respectively.[181] Current recommendations for DPI do not vary with age in adult MD patients, but this question has not been examined. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for energy intake in MHD and CPD patients recommend 35 kcal/kg per day for patients$<$60 years and 30 kcal/kg per day for MHD patients$\geq$60 years old.[181] Energy prescription can be increased for patients who are underweight, have PEW, or engage in chronic heavy physical activity, and it can be reduced in patients who are very obese.

Most people undergoing standard maintenance dialysis treatment will not be able to ingest these quantities of protein and energy, and their food intake may need to be augmented to meet these goals. In these circumstances, oral nutritional supplements can be used. Oral supplements of protein or primarily essential amino acids, usually including additional calories, may improve protein balance and PEW, promote protein accrual in SKM of people with ESRD, or prevent or retard the development of sarcopenia in elderly persons without CKD.[184–187] Tube feeding, intradialytic parenteral nutrition, or if necessary, total parenteral nutrition may be used for patients who are unable to take oral supplements.[188,189] Tube feeding, intradialytic parenteral nutrition, and provision of amino acids through peritoneal dialysate may increase protein balance.[182,190,191] Amino acids with or without glucose may be given through hemodialysate. The long-term nutritional or clinical benefits of all of these forms of nutritional support have not been well studied.[191] Nutritional support for elderly ESRD patients apparently has not been examined.

Metabolic Acidemia

Although the KDOQI Nutrition and KDOQI Bone Mineral Disease Clinical Practice Guidelines recommended serum bicarbonate$\geq$22 mEq/L,[181,192] recent evidence suggests that higher pH values may be more anabolic. An arterial blood pH of 7.45–7.45 compared with 7.36–7.38 may engender more positive protein balance in CPD patients.[142] CPD patients with plasma bicarbonate of 27.8$\pm$2.6 compared with 24.7$\pm$3.9 mmol/L (P=0.002) because of oral sodium bicarbonate treatment have a healthier higher subjective global assessment, increased nPNA (normalized total nitrogen appearance), and shorter hospitalizations.[193] MHD patients with mean arterial pH=7.44 and predialysis plasma bicarbonate=26.1 mEq/L showed greater growth hormone sensitivity compared with MHD patients with arterial pH=7.32 and plasma bicarbonate=20.4 mEq/L.[144] Moreover, a serum bicarbonate of about $<$23 mEq/L is associated with more rapid progression of CKD.[143,194–197] We suggest that, pending additional information, serum bicarbonate should probably be maintained above 24 mEq/L, and arterial blood pH should probably be maintained above 7.38 and possibly closer to 7.44 in CKD and ESRD patients.

Anabolic Agents

Publications dating back $>$50 years indicate that testosterone and other androgenic steroids may increase nitrogen balance and/or decrease serum urea or net protein breakdown in advanced CKD or dialysis patients.[198–201] More recent studies indicate that testosterone or other androgenic compounds may engender muscle hypertrophy and strength in dialysis patients.[202–204] Nandrolone decanoate increases lean body mass (LBM), and it improves walking, stair-climbing,[202] and quadriceps muscle cross-sectional area in maintenance dialysis patients.[205] Androgens may increase anabolism and strength in the elderly without CKD. A meta-analysis of 11 randomized, double-blind trials in elderly men without known CKD ages 69.1$\pm$3.3 years reported that testosterone replacement significantly increased muscle strength.[204] Carnitine also increases nitrogen balance in CPD patients (J.D. Kopple, unpublished observations).[206]

In MHD patients, GH increases muscle protein synthesis, reduces net protein catabolism,[207] lowers serum urea and urea nitrogen appearance,[208,209] induces positive protein balance,[210,211] reduces fat mass, increases LBM,[212–214] increases serum transferrin,[212,214] decreases serum high-sensitivity C-reactive protein,[214] improves SF-36 QOL,[212] and seems to be safe.[215] Not all studies report all of these positive results.[216] In a small, randomized study focused on older MHD patients (mean age=73 years, range=53–92 years), GH increased muscle cross-sectional area, LBM, serum albumin, hand grip strength, and walking speed and reduced fat mass.[217] Thus, GH also seems to be anabolic for elderly ESRD patients.

GH induces its anabolic effects primarily by stimulating IGF-1 production and release.[218] IGF-1 may ameliorate some of the age-related derangements in neuromuscular innervation and changes in muscle fiber types,[219] and it may improve excitation–contraction coupling in SKM.[220] Administration of IGF-1 also reduces serum urea and urea nitrogen appearance, and it increases nitrogen balance in CPD patients.[221] The side effect profile of IGF-1 is not as safe as GH, and IGF-1 has not been used in large clinical trials in CKD patients.[222,223] A cautionary note in this regard, as indicated above, some genes associated with longevity may attenuate the insulin/IGF pathways.[47,49,50] Whether chronic treatment with these anabolic hormones will reduce survival must be examined.

Exercise

Although many benefits are ascribed to exercise training of CKD and dialysis patients,[224] the most universally observed improvement is in endurance exercise capacity. Increased strength and physical performance are probably the next most commonly reported improvements.[31,205,225] Occasionally, exercise in nonelderly CKD or ESRD patients is reported to reduce inflammatory cytokines.[226,227] Increased muscle mass with exercise training is described less commonly. This finding may caused by less frequent or lower intensity strength training regimens for dialysis patients or their antianabolic status.[134] Muscle intracellular protein remodeling without hypertrophy seems to be common with exercise training.[134] Several studies have examined exercise training in elderly CKD patients. Twelve weeks of strength training of the thigh in elderly (76±7 years) stage 4–5 CKD patients significantly increased ($P<0.004$) muscular strength and walking capacity to a similar extent as in elderly healthy subjects.[228] MHD patients, ages 71±13 years, underwent low-intensity training of the leg and pelvic muscles.[229] Patients, compared with nonexercising controls, displayed increased lower extremity strength and leg and whole-body lean mass (DEXA), reduced body fat mass, and increased activities of daily living scores.

CONCLUSIONS

This review suggests that many causes may contribute to frailty and PEW in ESRD patients, and many potential strategies may prevent or reduce the severity of these disorders. Few, if any, of these methods have been tested in large randomized clinical trials in elderly ESRD patients. Many of the mechanisms engendering these disorders (and on which prevention and treatment strategies must be based) are still not well defined. The importance of some preventive and therapeutic approaches is intuitively obvious, such as inauguratation of dialysis therapy in a timely manner before frailty or PEW develop, aggressive evidence-based treatment of superimposed illnesses, and assurance of adequate nutrient intake. However, the optimal methods for such treatments often are not well defined. For example, the indications for starting dialysis are still imprecise. Similarly, the optimal nutrient intakes for the various clinical disorders encountered by a dialysis patient are not conclusively defined. Even more relevant, the clinical benefits of most preventative and therapeutic approaches listed in the text and Table 2 have not been shown in large-scale clinical trials in which QOL, morbidity, and mortality are used as key outcomes. The large and growing numbers of elderly ESRD patients coupled with the strong association of frailty and PEW with poor QOL and high morbidity and mortality provide a strong justification for directing more research effort and resources into investigating these questions.

ACKNOWLEDGMENTS

This manuscript was supported by National Institute of Diabetes, Digestive and Kidney Disease of the National Institutes of Health Research Grant R01-DK078106 and a philanthropist grant from Mr. Harold C. Simmons.

DISCLOSURES

K.K.-Z. has received honoraria from Abbott Nutrition and BBraun, the manufacturers of oral nutritional supplements for dialysis patients. J.D.K. is a consultant for Nephroceuticals.

REFERENCES

1. Oreopoulos DG, Dimkovic N: Geriatric nephrology is coming of age. *J Am Soc Nephrol* 14: 1099–1101, 2003
2. Brown EA, Johansson L: Old age and frailty in the dialysis population. *J Nephrol* 23: 502–507, 2010
3. Cavalli A, Del Vecchio L, Locatelli F: Geriatric nephrology. *J Nephrol* 23[Suppl 15]: S11–S15, 2010
4. US Renal Data System: *USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States*, Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive And Kidney Disease, 2010
5. Jassal SV, Chiu E, Li M: Geriatric hemodialysis rehabilitation care. *Adv Chronic Kidney Dis* 15: 115–122, 2008
6. Johansen KL, Chertow GM, Jin C, Kutner NG: Significance of frailty among dialysis patients. *J Am Soc Nephrol* 18: 2960–2967, 2007
7. Lacquaniti A, Bolignano D, Campo S, Perrone C, Donato V, Fazio MR, Buemi A, Sturiale A, Buemi M: Malnutrition in the elderly patient on dialysis. *Ren Fail* 31: 239–245, 2009
8. Foley RN, Wang C, Ishani A, Collins AJ, Murray AM: Kidney function and sarcopenia in the United States general population:

NHANES III. *Am J Nephrol* 27: 279–286, 2007
9. Dukkipati R, Kopple JD: Causes and prevention of protein-energy wasting in chronic kidney failure. *Semin Nephrol* 29: 39–49, 2009
10. Cook WL, Jassal SV: Functional dependencies among the elderly on hemodialysis. *Kidney Int* 73: 1289–1295, 2008
11. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: Evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 56: M146–M156, 2001
12. Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, Psaty BM, Newman AB: The presence of frailty in elderly persons with chronic renal insufficiency. *Am J Kidney Dis* 43: 861–867, 2004
13. Wilhelm-Leen ER, Hall YN, K Tamura M, Chertow GM: Frailty and chronic kidney disease: The Third National Health and Nutrition Evaluation Survey. *Am J Med* 122: 664–671, 2009
14. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int* 73: 391–398, 2008
15. Kopple JD: McCollum Award Lecture, 1996: Protein-energy malnutrition in maintenance dialysis patients. *Am J Clin Nutr* 65: 1544–1557, 1997
16. Warner HR, Sierra F, Thompson LV: Biology of aging. In: *Brocklehurst's Textbook of Geriatric Medicine and Gerontology*, 7th Ed., edited by Fillit HM, Rockwood K, Woodhouse K, Philadelphia, Saunders Elsevier, 2010, pp 30–37
17. Meng SJ, Yu LJ: Oxidative stress, molecular inflammation and sarcopenia. *Int J Mol Sci* 11: 1509–1526, 2010
18. Crowe AV, McArdle A, McArdle F, Pattwell DM, Bell GM, Kemp GJ, Bone JM, Griffiths RD, Jackson MJ: Markers of oxidative stress in the skeletal muscle of patients on haemodialysis. *Nephrol Dial Transplant* 22: 1177–1183, 2007
19. Howard C, Ferrucci L, Sun K, Fried LP, Walston J, Varadhan R, Guralnik JM, Semba RD: Oxidative protein damage is associated with poor grip strength among older women living in the community. *J Appl Physiol* 103: 17–20, 2007
20. Semba RD, Ferrucci L, Sun K, Walston J, Varadhan R, Guralnik JM, Fried LP: Oxidative stress and severe walking disability among older women. *Am J Med* 120: 1084–1089, 2007
21. Rosenberg IH: Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988. *Am J Clin Nutr* 50 [Suppl]: 1121–1235, 1989
22. Rosenberg IH: Sarcopenia: Origins and clinical relevance. *J Nutr* 127[Suppl]: 990S–991S, 1997
23. Clark BC, Manini TM: Sarcopenia =/= dynapenia. *J Gerontol A Biol Sci Med Sci* 63: 829–834, 2008
24. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Evans WJ, Fearon K, Ferrucci L, Fielding RA, Guralnik JM, Harris TB, Inui A, Kalantar-Zadeh K, Kirwan BA, Mantovani G, Muscaritoli M, Newman AB, Rossi-Fanelli F, Rosano GM, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von Haehling S, Yeh SS, Anker SD; Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop: Sarcopenia with limited mobility: An international consensus. *J Am Med Dir Assoc* 12: 403–409, 2011
25. Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ, Roubenoff R: Aging of skeletal muscle: A 12-yr longitudinal study. *J Appl Physiol* 88: 1321–1326, 2000
26. Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB, Luna A, Gomez M, Luna C, Bross R, Nissenson AR, Kalantar-Zadeh K: Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. *Clin J Am Soc Nephrol* 5: 2258–2268, 2010
27. Kalantar-Zadeh K, Streja E, Kovesdy CP, Oreopoulos A, Noori N, Jing J, Nissenson AR, Krishnan M, Kopple JD, Mehrotra R, Anker SD: The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. *Mayo Clin Proc* 85: 991–1001, 2010
28. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M, Newman AB, Goodpaster BH; Health, Aging, and Body: Longitudinal study of muscle strength, quality, and adipose tissue infiltration. *Am J Clin Nutr* 90: 1579–1585, 2009
29. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB: The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. *J Gerontol A Biol Sci Med Sci* 61: 1059–1064, 2006
30. Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, Fiatarone Singh MA: Longitudinal muscle strength changes in older adults: Influence of muscle mass, physical activity, and health. *J Gerontol A Biol Sci Med Sci* 56: B209–B217, 2001
31. Storer TW, Casaburi R, Sawelson S, Kopple JD: Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. *Nephrol Dial Transplant* 20: 1429–1437, 2005
32. Visser M, Deeg DJ, Lips P, Harris TB, Bouter LM: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. *J Am Geriatr Soc* 48: 381–386, 2000
33. Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. *J Gerontol A Biol Sci Med Sci* 61: 72–77, 2006
34. Cesari M, Pahor M, Lauretani F, Zamboni V, Bandinelli S, Bernabei R, Guralnik JM, Ferrucci L: Skeletal muscle and mortality results from the InCHIANTI Study. *J Gerontol A Biol Sci Med Sci* 64: 377–384, 2009
35. Baumgartner RN: Body composition in healthy aging. *Ann N Y Acad Sci* 904: 437–448, 2000
36. Shaw KA, Srikanth VK, Fryer JL, Blizzard L, Dwyer T, Venn AJ: Dual energy X-ray absorptiometry body composition and aging in a population-based older cohort. *Int J Obes (Lond)* 31: 279–284, 2007
37. Gallagher D, Ruts E, Visser M, Heshka S, Baumgartner RN, Wang J, Pierson RN, Pi-Sunyer FX, Heymsfield SB: Weight stability masks sarcopenia in elderly men and women. *Am J Physiol Endocrinol Metab* 279: E366–E375, 2000
38. Mehrotra R, Kopple JD: Nutritional management of maintenance dialysis patients: Why aren't we doing better? *Annu Rev Nutr* 21: 343–379, 2001
39. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergström J: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. *Kidney Int* 53: 773–782, 1998
40. Biasioli S, Foroni R, Petrosino L, Cavallini L, Zambello A, Cavalcanti G, Talluri T: Effect of aging on the body composition of dialyzed subjects. Comparison with normal subjects. *ASAIO J* 39: M596–M601, 1993
41. Kaizu Y, Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K, Kumagai H: Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. *Am J Kidney Dis* 42: 295–302, 2003
42. McIntyre CW, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF: Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. *Nephrol Dial Transplant* 21: 2210–2216, 2006
43. Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K, Kumagai H: Association of age with muscle mass, fat mass and fat distribution in

non-diabetic haemodialysis patients. *Nephrol Dial Transplant* 20: 945–951, 2005
44. Odamaki M, Furuya R, Ohkawa S, Yoneyama T, Nishikino M, Hishida A, Kumagai H: Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. *Nephrol Dial Transplant* 14: 2427–2432, 1999
45. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB; Women's Health Initiative: Frailty: Emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. *J Am Geriatr Soc* 53: 1321–1330, 2005
46. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB: Sarcopenia: Etiology, clinical consequences, intervention, and assessment. *Osteoporos Int* 21: 543–559, 2010
47. Barzilai N, Gabriely I, Atzmon G, Suh Y, Rothenberg D, Bergman A: Genetic studies reveal the role of the endocrine and metabolic systems in aging. *J Clin Endocrinol Metab* 95: 4493–4500, 2010
48. Fedarko NS: The biology of aging and frailty. *Clin Geriatr Med* 27: 27–37, 2011
49. Papaconstantinou J: Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. *Mol Cell Endocrinol* 299: 89–100, 2009
50. Berryman DE, Christiansen JS, Johannsson G, Thorner MO, Kopchick JJ: Role of the GH/IGF-1 axis in lifespan and healthspan: Lessons from animal models. *Growth Horm IGF Res* 18: 455–471, 2008
51. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. *N Engl J Med* 323: 1–6, 1990
52. Velloso CP: Regulation of muscle mass by growth hormone and IGF-I. *Br J Pharmacol* 154: 557–568, 2008
53. Gibney J, Healy ML, Sönksen PH: The growth hormone/insulin-like growth factor-I axis in exercise and sport. *Endocr Rev* 28: 603–624, 2007
54. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F: The GH/IGF1 axis and signaling pathways in the muscle and bone: Mechanisms underlying age-related skeletal muscle wasting and osteoporosis. *J Endocrinol* 205: 201–210, 2010
55. Hao CM, Haase VH: Sirtuins and their relevance to the kidney. *J Am Soc Nephrol* 21: 1620–1627, 2010
56. Weinberg JM: Mitochondrial biogenesis in kidney disease. *J Am Soc Nephrol* 22: 431–436, 2011
57. Wallace DC: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. *Annu Rev Genet* 39: 359–407, 2005
58. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R: Protein carbonyl groups as biomarkers of oxidative stress. *Clin Chim Acta* 329: 23–38, 2003
59. Beal MF: Oxidatively modified proteins in aging and disease. *Free Radic Biol Med* 32: 797–803, 2002
60. Salminen A, Ojala J, Kaarniranta K: Apoptosis and aging: Increased resistance to apoptosis enhances the aging process. *Cell Mol Life Sci* 68: 1021–1031, 2011
61. Salminen A, Kaarniranta K: Regulation of the aging process by autophagy. *Trends Mol Med* 15: 217–224, 2009
62. Sharpless NE, DePinho RA: How stem cells age and why this makes us grow old. *Nat Rev Mol Cell Biol* 8: 703–713, 2007
63. Zhu H, Belcher M, van der Harst P: Healthy aging and disease: Role for telomere biology? *Clin Sci (Lond)* 120: 427–440, 2011
64. Wills LP, Schnellmann RG: Telomeres and telomerase in renal health. *J Am Soc Nephrol* 22: 39–41, 2011
65. Yang H, Fogo AB: Cell senescence in the aging kidney. *J Am Soc Nephrol* 21: 1436–1439, 2010
66. Giunta S: Is inflammaging an auto[innate] immunity subclinical syndrome? *Immun Ageing* 3: 12, 2006
67. Chung HY, Kim HJ, Kim KW, Choi JS, Yu BP: Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. *Microsc Res Tech* 59: 264–272, 2002
68. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C: Molecular inflammation: Underpinnings of aging and age-related diseases. *Ageing Res Rev* 8: 18–30, 2009
69. Holick MF: High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc* 81: 353–373, 2006
70. Need AG, Morris HA, Horowitz M, Nordin C: Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D. *Am J Clin Nutr* 58: 882–885, 1993
71. Visser M, Deeg DJ, Lips P; Longitudinal Aging Study Amsterdam: Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. *J Clin Endocrinol Metab* 88: 5766–5772, 2003
72. Dawson-Hughes B: Serum 25-hydroxyvitamin D and functional outcomes in the elderly. *Am J Clin Nutr* 88: 537S–540S, 2008
73. Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: A randomized controlled trial. *Cerebrovasc Dis* 20: 187–192, 2005
74. Gordon PL, Sakkas GK, Doyle JW, Shubert T, Johansen KL: Relationship between vitamin D and muscle size and strength in patients on hemodialysis. *J Ren Nutr* 17: 397–407, 2007
75. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T: Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. *Endocrinology* 144: 5138–5144, 2003
76. Ceglia L: Vitamin D and its role in skeletal muscle. *Curr Opin Clin Nutr Metab Care* 12: 628–633, 2009
77. Delbono O: Neural control of aging skeletal muscle. *Aging Cell* 2: 21–29, 2003
78. Auyeung TW, Kwok T, Lee J, Leung PC, Leung J, Woo J: Functional decline in cognitive impairment—the relationship between physical and cognitive function. *Neuroepidemiology* 31: 167–173, 2008
79. Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA: Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. *Arch Neurol* 66: 1339–1344, 2009
80. Lexell J: Evidence for nervous system degeneration with advancing age. *J Nutr* 127 [Suppl]: 1011S–1013S, 1997
81. Christie A, Kamen G: Doublet discharges in motoneurons of young and older adults. *J Neurophysiol* 95: 2787–2795, 2006
82. Lauretani F, Bandinelli S, Bartali B, Di Iorio A, Giacomini V, Corsi AM, Guralnik JM, Ferrucci L: Axonal degeneration affects muscle density in older men and women. *Neurobiol Aging* 27: 1145–1154, 2006
83. Phillips T, Leeuwenburgh C: Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. *FASEB J* 19: 668–670, 2005
84. Kouidi E, Albani M, Natsis K, Megalopoulos A, Gigis P, Guiba-Tziampiri O, Tourkantonis A, Deligiannis A: The effects of exercise training on muscle atrophy in haemodialysis patients. *Nephrol Dial Transplant* 13: 685–699, 1998
85. Conboy IM, Conboy MJ, Smythe GM, Rando TA: Notch-mediated restoration of regenerative potential to aged muscle. *Science* 302: 1575–1577, 2003
86. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ: Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. *Am J Physiol Endocrinol Metab* 292: E151–E157, 2007
87. Bigot A, Jacquemin V, Debacq-Chainiaux F, Butler-Browne GS, Toussaint O, Furling D, Mouly V: Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. *Biol Cell* 100: 189–199, 2008
88. Faulkner JA, Larkin LM, Claflin DR, Brooks SV: Age-related changes in the structure and function of skeletal muscles. *Clin Exp Pharmacol Physiol* 34: 1091–1096, 2007

89. Campbell MJ, McComas AJ, Petito F: Physiological changes in ageing muscles. *J Neurol Neurosurg Psychiatry* 36: 174–182, 1973
90. Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor PM, Rennie MJ: Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. *FASEB J* 19: 422–424, 2005
91. Narici MV, Maganaris CN: Adaptability of elderly human muscles and tendons to increased loading. *J Anat* 208: 433–443, 2006
92. Murphey MD, Sartoris DJ, Quale JL, Pathria MN, Martin NL: Musculoskeletal manifestations of chronic renal insufficiency. *Radiographics* 13: 357–379, 1993
93. Thaunat M, Gaudin P, Naret C, Beaufils P, Thaunat O: Role of secondary hyperparathyroidism in spontaneous rupture of the quadriceps tendon complicating chronic renal failure. *Rheumatology (Oxford)* 45: 234–235, 2006
94. Kalantar-Zadeh K, Singh K, Kleiner M, Jarrett MP, Luft FC: Nontraumatic bilateral rupture of patellar tendons in a diabetic dialysis patient with secondary hyperparathyroidism. *Nephrol Dial Transplant* 12: 1988–1990, 1997
95. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int* 70: 1358–1366, 2006
96. Jadoul M: Towards the prevention of bone fractures in dialysed patients? *Nephrol Dial Transplant* 22: 3377–3380, 2007
97. Aparicio M, Cano N, Chauveau P, Azar R, Canaud B, Flory A, Laville M, Leverve X; French Study Group for Nutrition in Dialysis: Nutritional status of haemodialysis patients: A French national cooperative study. *Nephrol Dial Transplant* 14: 1679–1686, 1999
98. Cotter KA, Lachman ME: No strain, no gain: Psychosocial predictors of physical activity across the adult lifespan. *J Phys Act Health* 7: 584–594, 2010
99. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, Kent-Braun JA: Physical activity levels in patients on hemodialysis and healthy sedentary controls. *Kidney Int* 57: 2564–2570, 2000
100. Stack AG, Murthy B: Exercise and limitations in physical activity levels among new dialysis patients in the United States: An epidemiologic study. *Ann Epidemiol* 18: 880–888, 2008
101. Johansen KL, Chertow GM, Kutner NG, Dalrymple LS, Grimes BA, Kaysen GA: Low level of self-reported physical activity in ambulatory patients new to dialysis. *Kidney Int* 78: 1164–1170, 2010
102. Majchrzak KM, Pupim LB, Sundell M, Ikizler TA: Body composition and physical activity in end-stage renal disease. *J Ren Nutr* 17: 196–204, 2007
103. Kutsuna T, Matsunaga A, Matsumoto T, Ishii A, Yamamoto K, Hotta K, Aiba N, Takagi Y, Yoshida A, Takahira N, Masuda T: Physical activity is necessary to prevent deterioration of the walking ability of patients undergoing maintenance hemodialysis. *Ther Apher Dial* 14: 193–200, 2010
104. Stack AG, Molony DA, Rives T, Tyson J, Murthy BV: Association of physical activity with mortality in the US dialysis population. *Am J Kidney Dis* 45: 690–701, 2005
105. Bossola M, Tazza L, Giungi S, Luciani G: Anorexia in hemodialysis patients: An update. *Kidney Int* 70: 417–422, 2006
106. Suri RS, Nesrallah GE, Mainra R, Garg AX, Lindsay RM, Greene T, Daugirdas JT: Daily hemodialysis: A systematic review. *Clin J Am Soc Nephrol* 1: 33–42, 2006
107. Rousset S, Patureau Mirand P, Brandolini M, Martin JF, Boirie Y: Daily protein intakes and eating patterns in young and elderly French. *Br J Nutr* 90: 1107–1115, 2003
108. Mekki K, Remaoun M, Belleville J, Bouchenak M: Hemodialysis duration impairs food intake and nutritional parameters in chronic kidney disease patients. *Int Urol Nephrol* 44: 237–244, 2010
109. Raj DS, Sun Y, Tzamaloukas AH: Hypercatabolism in dialysis patients. *Curr Opin Nephrol Hypertens* 17: 589–594, 2008
110. Aguilera A, Codoceo R, Selgas R, Garcia P, Picornell M, Diaz C, Sanchez C, Bajo MA: Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: Their relationship with nutritional parameters. *Nephrol Dial Transplant* 13: 1476–1483, 1998
111. Mak RH, Cheung W, Cone RD, Marks DL: Leptin and inflammation-associated cachexia in chronic kidney disease. *Kidney Int* 69: 794–797, 2006
112. da Costa JA, Ikizler TA: Inflammation and insulin resistance as novel mechanisms of wasting in chronic dialysis patients. *Semin Dial* 22: 652–657, 2009
113. Utaka S, Avesani CM, Draibe SA, Kamimura MA, Andreoni S, Cuppari L: Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. *Am J Clin Nutr* 82: 801–805, 2005
114. Nicklas BJ, Brinkley TE: Exercise training as a treatment for chronic inflammation in the elderly. *Exerc Sport Sci Rev* 37: 165–170, 2009
115. Raj DS, Dominic EA, Pai A, Osman F, Morgan M, Pickett G, Shah VO, Ferrando A, Moseley P: Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. *Kidney Int* 68: 2338–2344, 2005
116. Dursun E, Ozben T, Suleymanlar G, Dursun B, Yakupoglu G: Effect of hemodialysis on the oxidative stress and antioxidants. *Clin Chem Lab Med* 40: 1009–1013, 2002
117. Sanz A, Stefanatos RK: The mitochondrial free radical theory of aging: A critical view. *Curr Aging Sci* 1: 10–21, 2008
118. Hekimi S, Lapointe J, Wen Y: Taking a "good" look at free radicals in the aging process. *Trends Cell Biol* 21: 569–576, 2011
119. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. *Kidney Int* 58: 2571–2578, 2000
120. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J: Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. *Clin J Am Soc Nephrol* 3: 691–698, 2008
121. Miyata T, Saito A, Kurokawa K, van Ypersele de Strihou C: Advanced glycation and lipoxidation end products: Reactive carbonyl compounds-related uraemic toxicity. *Nephrol Dial Transplant* 16[Suppl 4]: 8–11, 2001
122. Satko SG, Sedor JR, Iyengar SK, Freedman BI: Familial clustering of chronic kidney disease. *Semin Dial* 20: 229–236, 2007
123. Lea JP, McClellan WM, Melcher C, Gladstone E, Hostetter T: CKD risk factors reported by primary care physicians: Do guidelines make a difference? *Am J Kidney Dis* 47: 72–77, 2006
124. Stenvinkel P, Ekström TJ: Epigenetics—a helpful tool to better understand processes in clinical nephrology? *Nephrol Dial Transplant* 23: 1493–1496, 2008
125. Salminen A, Kaarniranta K: Genetics vs. entropy: Longevity factors suppress the NF-kappaB-driven entropic aging process. *Ageing Res Rev* 9: 298–314, 2010
126. Sun DF, Zheng Z, Tummala P, Oh J, Schaefer F, Rabkin R: Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. *J Am Soc Nephrol* 15: 2630–2636, 2004
127. Siew ED, Ikizler TA: Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. *Semin Dial* 23: 378–382, 2010
128. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA: Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. *Kidney Int* 71: 146–152, 2007
129. Workeneh BT, Mitch WE: Review of muscle wasting associated with chronic kidney disease. *Am J Clin Nutr* 91: 1128S–1132S, 2010
130. Pupim LB, Heimbürger O, Qureshi AR, Ikizler TA, Stenvinkel P: Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. *Kidney Int* 68: 2368–2374, 2005
131. Pupim LB, Flakoll PJ, Majchrzak KM, Aftab Guy DL, Stenvinkel P, Ikizler TA: Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. *Kidney Int* 68: 1857–1865, 2005

132. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Cho YW, Newman AB; Health, Aging, and Body Composition Study: Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: The health, aging, and body composition study. *Diabetes Care* 30: 1507–1512, 2007
133. Ding H, Gao XL, Hirschberg R, Vadgama JV, Kopple JD: Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a post-receptor defect. *J Clin Invest* 97: 1064–1075, 1996
134. Kopple JD, Wang H, Casaburi R, Fournier M, Lewis MI, Taylor W, Storer TW: Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. *J Am Soc Nephrol* 18: 2975–2986, 2007
135. Wang H, Casaburi R, Taylor WE, Aboellail H, Storer TW, Kopple JD: Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients. *Kidney Int* 68: 352–361, 2005
136. Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, Barany P, Heimburger O, Stenvinkel P: Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. *Nephrol Dial Transplant* 26: 184–190, 2011
137. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB: Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. *J Clin Endocrinol Metab* 87: 589–598, 2002
138. Cawthon PM, Ensrud KE, Laughlin GA, Cauley JA, Dam TT, Barrett-Connor E, Fink HA, Hoffman AR, Lau E, Lane NE, Stefanick ML, Cummings SR, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Research Group: Sex hormones and frailty in older men: The osteoporotic fractures in men (MrOS) study. *J Clin Endocrinol Metab* 94: 3806–3815, 2009
139. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. *N Engl J Med* 335: 1–7, 1996
140. Rajan V, Mitch WE: Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease. *Biochim Biophys Acta* 795-9: 2008, 1782
141. Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. *N Engl J Med* 335: 1897–1905, 1996
142. Mehrotra R, Bross R, Wang H, Appell M, Tso L, Kopple JD: Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients. *Am J Clin Nutr* 90: 1532–1540, 2009
143. Kraut JA, Kurtz I: Metabolic acidosis of CKD: Diagnosis, clinical characteristics, and treatment. *Am J Kidney Dis* 45: 978–993, 2005
144. Wiederkehr MR, Kalogiros J, Krapf R: Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. *Nephrol Dial Transplant* 19: 1190–1197, 2004
145. Kopple JD, Kalantar-Zadeh K, Mehrotra R: Risks of chronic metabolic acidosis in patients with chronic kidney disease. *Kidney Int Suppl* 95: S21–S27, 2005
146. Jamal SA, Leiter RE, Jassal V, Hamilton CJ, Bauer DC: Impaired muscle strength is associated with fractures in hemodialysis patients. *Osteoporos Int* 17: 1390–1397, 2006
147. Cheema B, Abas H, Smith B, O'Sullivan AJ, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, Berger K, Baune BT, Singh MF: Investigation of skeletal muscle quantity and quality in end-stage renal disease. *Nephrology (Carlton)* 15: 454–463, 2010
148. Johansen KL, Shubert T, Doyle J, Soher B, Sakkas GK, Kent-Braun JA: Muscle atrophy in patients receiving hemodialysis: Effects on muscle strength, muscle quality, and physical function. *Kidney Int* 63: 291–297, 2003
149. Kaysen GA, Larive B, Painter P, Craig A, Lindsay RM, Rocco MV, Daugirdas JT, Schulman G, Chertow GM, Group FHNT: Baseline physical performance, health, and functioning of participants in the Frequent Hemodialysis Network (FHN) trial. *Am J Kidney Dis* 57: 101–112, 2011
150. Sterky E, Stegmayr BG: Elderly patients on haemodialysis have 50% less functional capacity than gender- and age-matched healthy subjects. *Scand J Urol Nephrol* 39: 423–430, 2005
151. Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA: Frailty is associated with incident Alzheimer's disease and cognitive decline in the elderly. *Psychosom Med* 69: 483–489, 2007
152. Bouchard DR, Janssen I: Dynapenic-obesity and physical function in older adults. *J Gerontol A Biol Sci Med Sci* 65: 71–77, 2010
153. Bouchard DR, Beliaeff S, Dionne IJ, Brochu M: Fat mass but not fat-free mass is related to physical capacity in well-functioning older individuals: Nutrition as a determinant of successful aging (NuAge)—the Quebec Longitudinal Study. *J Gerontol A Biol Sci Med Sci* 62: 1382–1388, 2007
154. Pijnappels M, van der Burg PJ, Reeves ND, van Dieën JH: Identification of elderly fallers by muscle strength measures. *Eur J Appl Physiol* 102: 585–592, 2008
155. Cook WL, Jassal SV: Prevalence of falls among seniors maintained on hemodialysis. *Int Urol Nephrol* 37: 649–652, 2005
156. Cook WL, Tomlinson G, Donaldson M, Markowitz SN, Naglie G, Sobolev B, Jassal SV: Falls and fall-related injuries in older dialysis patients. *Clin J Am Soc Nephrol* 1: 1197–1204, 2006
157. Desmet C, Beguin C, Swine C, Jadoul M; Universite Catholique de Louvain Collaborative: Falls in hemodialysis patients: Prospective study of incidence, risk factors, and complications. *Am J Kidney Dis* 45: 148–153, 2005
158. Li M, Tomlinson G, Naglie G, Cook WL, Jassal SV: Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. *Nephrol Dial Transplant* 23: 1396–1400, 2008
159. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. *Am J Kidney Dis* 47: 149–156, 2006
160. Kalantar-Zadeh K: Causes and consequences of the reverse epidemiology of body mass index in dialysis patients. *J Ren Nutr* 15: 142–147, 2005
161. Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D: Is there any survival advantage of obesity in Southern European haemodialysis patients? *Nephrol Dial Transplant* 24: 2871–2876, 2009
162. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. *Kidney Int* 63: 793–808, 2003
163. Beddhu S, Pappas LM, Ramkumar N, Samore M: Effects of body size and body composition on survival in hemodialysis patients. *J Am Soc Nephrol* 14: 2366–2372, 2003
164. Ramkumar N, Pappas LM, Beddhu S: Effect of body size and body composition on survival in peritoneal dialysis patients. *Perit Dial Int* 25: 461–469, 2005
165. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB: Survival advantages of obesity in dialysis patients. *Am J Clin Nutr* 81: 543–554, 2005
166. Kalantar-Zadeh K, Kopple JD: Obesity paradox in patients on maintenance dialysis. *Contrib Nephrol* 151: 57–69, 2006
167. Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, Block G, Kopple JD: Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. *Am J Clin Nutr* 83: 202–210, 2006
168. Antunes AA, Delatim Vannini F, de Arruda Silveira LV, Martin LC, Barretti P, Caramori JC: Influence of protein intake and muscle mass on survival in chronic dialysis patients. *Ren Fail* 32: 1055–1059, 2010
169. Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, Stenvinkel P, Lindholm B: Obese sarcopenia in patients with end-stage renal disease

is associated with inflammation and increased mortality. *Am J Clin Nutr* 86: 633–638, 2007
170. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimbürger O, Axelsson J, Bárány P, Lindholm B, Carrero JJ: Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. *Nephrol Dial Transplant* 25: 562–568, 2010
171. Chung SH, Lindholm B, Lee HB: Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. *Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis* 20**:** 19-26, 2000
172. Iseki K, Uehara H, Nishime K, Tokuyama K, Yoshihara K, Kinjo K, Shiohira Y, Fukiyama K: Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. *Am J Kidney Dis* 28: 541–548, 1996
173. Goldwasser P, Kaldas AI, Barth RH: Rise in serum albumin and creatinine in the first half year on hemodialysis. *Kidney Int* 56: 2260–2268, 1999
174. Mehrotra R, Berman N, Alistwani A, Kopple JD: Improvement of nutritional status after initiation of maintenance hemodialysis. *Am J Kidney Dis* 40: 133–142, 2002
175. Schulman G: Nutrition in daily hemodialysis. *Am J Kidney Dis* 41[Suppl 1]: S112–S115, 2003
176. Coombes JS, Fassett RG: Antioxidant therapy in hemodialysis patients: A systematic review. *Kidney Int* 81: 233–246,2011
177. Iglesias P, Diez JJ: Peroxisome proliferator-activated receptor gamma agonists in renal disease. *Eur J Endocrinol* 154: 613–621, 2006
178. Kumar S, Raftery M, Yaqoob M, Fan SL: Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. *Perit Dial Int* 27: 283–287, 2007
179. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. *Lancet* 356: 1213–1218, 2000
180. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. *Circulation* 107: 992–995, 2003
181. Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines for nutrition in chronic renal failure. *Am J Kidney Dis* 35: S38–S39, 2000
182. Dukkipati R, Noori N, Feroze U, Kopple JD: Dietary protein intake in patients with advanced chronic kidney disease and on dialysis. *Semin Dial* 23: 365–372, 2010
183. Kovesdy CP, Shinaberger CS, Kalantar-Zadeh K: Epidemiology of dietary nutrient intake in ESRD. *Semin Dial* 23: 353–358, 2010
184. Paddon-Jones D, Short KR, Campbell WW, Volpi E, Wolfe RR: Role of dietary protein in the sarcopenia of aging. *Am J Clin Nutr* 87: 1562S–1566S, 2008
185. Volpi E, Kobayashi H, Sheffield-Moore M, Mittendorfer B, Wolfe RR: Essential amino acids are primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy elderly adults. *Am J Clin Nutr* 78: 250–258, 2003
186. Rieu I, Balage M, Sornet C, Giraudet C, Pujos E, Grizard J, Mosoni L, Dardevet D: Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia. *J Physiol* 575: 305–315, 2006
187. Paddon-Jones D, Rasmussen BB: Dietary protein recommendations and the prevention of sarcopenia. *Curr Opin Clin Nutr Metab Care* 12: 86–90, 2009
188. Stratton RJ, Bircher G, Fouque D, Stenvinkel P, de Mutsert R, Engfer M, Elia M: Multinutrient oral supplements and tube feeding in maintenance dialysis: A systematic review and meta-analysis. *Am J Kidney Dis* 46: 387–405, 2005
189. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA: Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. *J Clin Invest* 110: 483–492, 2002
190. Dong J, Ikizler TA: New insights into the role of anabolic interventions in dialysis patients with protein energy wasting. *Curr Opin Nephrol Hypertens* 18: 469–475, 2009
191. Dukkipati R, Kalantar-Zadeh K, Kopple JD: Is there a role for intradialytic parenteral nutrition? A review of the evidence. *Am J Kidney Dis* 55: 352–364, 2010
192. KDOQI: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 42: S129–S130, 2003
193. Szeto CC, Wong TY, Chow KM, Leung CB, Li PK: Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: A randomized placebo-control trial. *J Am Soc Nephrol* 14: 2119–2126, 2003
194. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM: Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am Soc Nephrol* 20: 2075–2084, 2009
195. Shah SN, Abramowitz M, Hostetter TH, Melamed ML: Serum bicarbonate levels and the progression of kidney disease: A cohort study. *Am J Kidney Dis* 54: 270–277, 2009
196. Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. *Kidney Int* 77: 617–623, 2010
197. Gadola L, Noboa O, Márquez MN, Rodriguez MJ, Nin N, Boggia J, Ferreiro A, García S, Ortega V, Musto ML, Ponte P, Sesser P, Pizarrosa C, Ravaglio S, Vallega A: Calcium citrate ameliorates the progression of chronic renal injury. *Kidney Int* 65: 1224–1230, 2004
198. Gjorup S, Thaysen JH: Anabolic steroids in treatment of uraemia. *Lancet* 2: 886–887, 1958
199. Snyder D, Brest AN: Chronic renal insufficiency treated with anabolic steroids: Effects on acid-base balance, protein metabolism and hematopoiesis. *J Am Geriatr Soc* 14: 21–32, 1966
200. Lindner A, Tenckhoff H: Influence of anabolic steroids on nitrogen balance in chronic peritoneal dialysis. *Nephron* 9: 77–85, 1972
201. Lindner A, Tenckhoff H: Nitrogen balance in patients on maintenance peritoneal dialysis. *Trans Am Soc Artif Intern Organs* 16: 255–259, 1970
202. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. *JAMA* 281: 1275–1281, 1999
203. Johansen KL: Testosterone metabolism and replacement therapy in patients with end-stage renal disease. *Semin Dial* 17: 202–208, 2004
204. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV: Androgen treatment and muscle strength in elderly men: A meta-analysis. *J Am Geriatr Soc* 54: 1666–1673, 2006
205. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. *J Am Soc Nephrol* 17: 2307–2314, 2006
206. Kopple JD, Qing D: Effect of L-carnitine on nitrogen balance in CAPD patient. *J Am Soc Nephrol* 10: 264A, 1999
207. Garibotto G, Barreca A, Russo R, Sofia A, Araghi P, Cesarone A, Malaspina M, Fiorini F, Minuto F, Tizianello A: Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. *J Clin Invest* 99: 97–105, 1997
208. Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW: Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. *J Am Soc Nephrol* 2: 1130–1135, 1991

209. Schulman G, Wingard RL, Hutchison RL, Lawrence P, Hakim RM: The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. *Am J Kidney Dis* 21: 527–534, 1993
210. Kopple JD, Brunori G, Leiserowitz M, Fouque D: Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. *Nephrol Dial Transplant* 20: 952–958, 2005
211. Guebre-Egziabher F, Juillard L, Boirie Y, Laville M, Beaufrère B, Fouque D: Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis. *J Clin Endocrinol Metab* 94: 2299–2305, 2009
212. Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M; APCD Study Group: Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. *J Am Soc Nephrol* 18: 2161–2171, 2007
213. Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB: Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. *Clin Nephrol* 53: 99–107, 2000
214. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Mitch WE, Wanner C, Gothberg M, Ikizler TA: OPPORTUNITY™: A large-scale randomized clinical trial of growth hormone in hemodialysis patients. *Nephrol Dial Transplant* 26: 4095–4103, 2011
215. Langbakke IH, Nielsen JN, Skettrup MP, Harper A, Klitgaard T, Weil A, Engelhardt E, Lange M: Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: An open, non-randomized, parallel-group trial. *Clin Endocrinol (Oxf)* 67: 776–783, 2007
216. Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuzer S, Geyer G, Frisch H, Hörl WH, Mayer G, Luger A: Differential effects of growth hormone therapy in malnourished hemodialysis patients. *Kidney Int* 60: 1578–1585, 2001
217. Johannsson G, Bengtsson BA, Ahlmén J: Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: Anabolic effect and functional improvement. *Am J Kidney Dis* 33: 709–717, 1999
218. Blake PG: Growth hormone and malnutrition in dialysis patients. *Perit Dial Int* 15: 210–216, 1995
219. Messi ML, Delbono O: Target-derived trophic effect on skeletal muscle innervation in senescent mice. *J Neurosci* 23: 1351–1359, 2003
220. Schertzer JD, van der Poel C, Shavlakadze T, Grounds MD, Lynch GS: Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. *Am J Physiol Cell Physiol* 294: C161–C168, 2008
221. Fouque D, Peng SC, Shamir E, Kopple JD: Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. *Kidney Int* 57: 646–654, 2000
222. Fouque D, Tayek JA, Kopple JD: Altered mental function during intravenous infusion of recombinant human insulin-like growth factor 1. *JPEN J Parenter Enteral Nutr* 19: 231–233, 1995
223. O'Shea MH, Miller SB, Hammerman MR: Effects of IGF-I on renal function in patients with chronic renal failure. *Am J Physiol* 264: F917–F922, 1993
224. Kopple JD, Storer T, Casburi R: Impaired exercise capacity and exercise training in maintenance hemodialysis patients. *J Ren Nutr* 15: 44–48, 2005
225. Painter P, Carlson L, Carey S, Paul SM, Myll J: Low-functioning hemodialysis patients improve with exercise training. *Am J Kidney Dis* 36: 600–608, 2000
226. Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS: Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. *Am J Kidney Dis* 43: 607–616, 2004
227. Cheema B, Abas H, Smith B, O'Sullivan A, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, Singh MF: Progressive exercise for anabolism in kidney disease (PEAK): A randomized, controlled trial of resistance training during hemodialysis. *J Am Soc Nephrol* 18: 1594–1601, 2007
228. Heiwe S, Tollbäck A, Clyne N: Twelve weeks of exercise training increases muscle function and walking capacity in elderly predialysis patients and healthy subjects. *Nephron* 88: 48–56, 2001
229. Chen JL, Godfrey S, Ng TT, Moorthi R, Liangos O, Ruthazer R, Jaber BL, Levey AS, Castaneda-Sceppa C: Effect of intradialytic, low-intensity strength training on functional capacity in adult haemodialysis patients: A randomized pilot trial. *Nephrol Dial Transplant* 25: 1936–1943, 2010